Navigation Links
Biomatrica Announces the Appointment of Dr. James A. Robb as a Member of the Scientific Advisory Board
Date:5/26/2011

w technologies that deliver significant cost savings, superior logistics to cold handling and storage, without compromising biospecimen quality and integrity. All of these benefits are found in the technologies that have been and are being developed at Biomatrica, and I am delighted to serve on the company's Scientific Advisory Board."  

"Biomatrica is proud to have Dr. Robb join our SAB team bringing a wealth of experience, expertise and knowledge in clinical and molecular diagnostics for disease management and stratification," says Dr. Rolf Muller, Biomatrica's Chief Scientific Officer, President and Founder. "Dr. Robb will play a key role in helping Biomatrica chart a new course with new technologies under development designed for efficient management of critical biological samples for use in clinical trials, diagnostics, biobanking, genomics research, as well as forensic investigations. With Jim joining our SAB, we believe that Biomatrica is primed to become the leader in ambient stabilization for all biosamples and create the types of solutions that support and enhance better management of samples for advancing globalized health care and personalized medicine."

About Biomatrica, Inc.

Biomatrica (www.biomatrica.com) is a San Diego-based biostability company that provides innovative technologies for stabilizing, processing, storing, shipping and assaying biological samples at room temperature. The core technology is designed for use in preserving complex biological samples and assays and is based on the principles of anhydrobiosis ("life without water"), a natural mechanism that allows multicellular organisms to survive extreme environments. Biomatrica's current products stabilize DNA and RNA with no sample degradation, thus labs can reduce their reliance on freezers and drastically reduce shipping costs. Biomatrica products are used in laboratories performing life science research, from p
'/>"/>

SOURCE Biomatrica
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biomatrica Launches New Partnership Program - Biomatrica Connect(TM)
2. Biomatrica Launches SampleWare 3.1
3. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
4. Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan
5. Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatricas Room Temperature Storage
6. Sequenom Announces Participation at Jefferies 2011 Global Healthcare Conference
7. WaferGen Announces $30 Million Financing
8. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
9. Vermillion Announces Notice of Allowance for Alzheimer Patent
10. VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
11. Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... The Dohmen Company today announced the ... as Chief Science Officer (CSO) of Dohmen Life ... Dr. Floyd will lead Dohmen,s growing regulatory consulting ... and post approval outsourced services in quality, regulatory, ... Floyd brings decades of experience leading global regulatory ...
(Date:9/1/2015)... MA (PRWEB) , ... September 01, 2015 , ... ... its new Director of Business Development, Asia Pacific. In this newly-created position, Gibbs ... the awareness and use of iLab’s suite of tools. This entails not only ...
(Date:9/1/2015)... -- Shire plc (LSE: SHP, NASDAQ: SHPG ... its Board of Directors as a Non-Executive Director. Sara will ... Committee of the Shire Board. Both appointments will be effective ... as Chairman, President and Chief Executive Officer of Dun & ... tenure at D&B, she helped drive the transformation of the ...
(Date:8/31/2015)... DIEGO , Aug. 31, 2015 MabVax ... development company announces that the Company,s lead antibody, HuMab ... of five separate presentations during the upcoming World Molecular ... September 2-5, 2015. Researchers from the Department ... will present results on the use of MabVax,s lead ...
Breaking Biology Technology:Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Shire Appoints Sara Mathew to Board of Directors 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4
... , , , 7.6.4 Long PCR , ... as desired with every temperature , command, enables a , ... , With Long PCR, this function can be used ... elongation. , , ...
... , , , , , ... set of conditions that can be applied to all PCR amplifications. For ... used, the annealing temperatures , of the PCRs can differ ... stringent annealing temperature is a prerequisite for reliable results , ...
... , , , , ... fragment using the PCR* are an everyday occurrence in the lab. For example, , ... which hinder, , or even prevent, further analyses (cycle ... of the PCR result. In such cases, PCR , ...
Cached Biology Technology:PCR Optimization 2PCR Optimization 3Using Gradient PCR to determine the optimum annealing temperature. 2
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... acetyl CoA carboxylase 2,or ACC2, appears to turn the ... in part why the animals can eat more and ... Medicine,researchers.,The report that appears online today in the Proceedings ... cells in these mice bred to lack ACC2," said ...
... University,of California, San Diego have invented a process ... of specialized cells being sought as possible,treatments for ... and Shu Chien, UCSD bioengineering professors, and Christopher,J. ... in a paper published in the February issue ...
... have discovered a way to overcome one of the ... kill normal cells in the,process of eradicating cancer cells.,In ... of the Proceedings of the,National Academy of Sciences (PNAS), ... into a specially designed,virus. The virus eradicated prostate cancer ...
Cached Biology News:Lack of enzyme turns fat cells into fat burners 2Priming embryonic stem cells to fulfill their promise 2Priming embryonic stem cells to fulfill their promise 3Columbia research lifts major hurdle to gene therapy for cancer 2